Process Development

Working with Cambrex and Snapdragon Chemistry, our clients benefit from a proactive and phase-appropriate approach to API process development and validation, as well as access to advanced technology and industry-leading expertise in autonomous process development.

Early drug development studies are traditionally designed to support fit-for-purpose manufacture of early clinical materials. Our scientists can suggest process improvements early to:

  • Reduce the number of transformations required to synthesize a given molecule
  • Improve the efficiency of the transformations

If looking to establish a continuous process, our laboratory services can support the implementation to prepare scaled quantities of your target product. We can also work with your in-house team to design and build process-scale reactors to ensure seamless technology transfer.

Some of the reactors we use to develop autonomous processes for our clients include:

  • Plug Flow reactors
  • Packed Bed reactors
  • Continuous Stirred-tank Reactors (CSTRs)
  • Photoreactors
  • Electrochemical reactors

As molecules progress, we help to create more cost-effective, robust and safe processes to manufacture your active ingredient for pilot and commercial production. Cambrex excels at turning early routes into commercially viable manufacturing routes during the drug development cycle.

We are structured to oversee custom small-molecule process development from early clinical phase to commercial production, and we offer a flexible manufacturing landscape, with small-, mid- and large-scale facilities designed to support customized solutions and seamless transfer of technologies.

Our development teams specialize in finding creative solutions to early-phase challenges while remaining focused on the rigors of validation. As a result, we can help you to avoid late-stage process changes, which could impact your speed to market. The result is more efficient preparation of your APIs and intermediates and greater confidence in your project’s success.